NLS Pharmaceutics (NLSP) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
NLS Pharmaceutics is advancing its preclinical program centered on dual orexin receptor agonists (DOXA) aimed at treating narcolepsy and other neurological disorders. The innovative approach using AEX-41 and AEX-2 targets multiple receptors and promises better therapeutic outcomes compared to existing treatments. As the company progresses, investors eagerly await initial results expected this December, with potential expansions into other conditions like ALS.
For further insights into NLSP stock, check out TipRanks’ Stock Analysis page.
